Cargando…

Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Albert C M, Torra, Roser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155227/
https://www.ncbi.nlm.nih.gov/pubmed/35664267
http://dx.doi.org/10.1093/ckj/sfac103
_version_ 1784718198530113536
author Ong, Albert C M
Torra, Roser
author_facet Ong, Albert C M
Torra, Roser
author_sort Ong, Albert C M
collection PubMed
description Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in clinical practice is whether there is anything they can do to slow their disease by modifying their diet or lifestyle. Recent evidence from experimental PKD models has shown the potential benefits of caloric restriction, high water intake and especially ketogenic diets in preserving kidney function. Whether these benefits are translatable to humans remains unknown. In this issue of CKJ, Strubl et al. report results of a self-enrolled survey of autosomal dominant polycystic kidney disease (ADPKD) patients who have self-administered a ketogenic diet [1]. These results provide interesting insights into the tolerability, potential benefits and harms of such an intervention that could inform a future clinical trial.
format Online
Article
Text
id pubmed-9155227
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91552272022-06-04 Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't Ong, Albert C M Torra, Roser Clin Kidney J Editorial Comment Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in clinical practice is whether there is anything they can do to slow their disease by modifying their diet or lifestyle. Recent evidence from experimental PKD models has shown the potential benefits of caloric restriction, high water intake and especially ketogenic diets in preserving kidney function. Whether these benefits are translatable to humans remains unknown. In this issue of CKJ, Strubl et al. report results of a self-enrolled survey of autosomal dominant polycystic kidney disease (ADPKD) patients who have self-administered a ketogenic diet [1]. These results provide interesting insights into the tolerability, potential benefits and harms of such an intervention that could inform a future clinical trial. Oxford University Press 2022-04-21 /pmc/articles/PMC9155227/ /pubmed/35664267 http://dx.doi.org/10.1093/ckj/sfac103 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Editorial Comment
Ong, Albert C M
Torra, Roser
Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title_full Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title_fullStr Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title_full_unstemmed Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title_short Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
title_sort can ketogenic dietary interventions slow disease progression in adpkd: what we know and what we don't
topic Editorial Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155227/
https://www.ncbi.nlm.nih.gov/pubmed/35664267
http://dx.doi.org/10.1093/ckj/sfac103
work_keys_str_mv AT ongalbertcm canketogenicdietaryinterventionsslowdiseaseprogressioninadpkdwhatweknowandwhatwedont
AT torraroser canketogenicdietaryinterventionsslowdiseaseprogressioninadpkdwhatweknowandwhatwedont